Long-Acting Formulations of Atypical Antipsychotics: Time to Reconsider When to Introduce Depot Antipsychotics

ISSN： 1172-7047

Source： CNS Drugs, Vol.21, Iss.6, 2007-01, pp. : 441-448

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

By Bhanji N.H. Chouinard G. Margolese H.C.

European Neuropsychopharmacology, Vol. 14, Iss. 2, 2004-03 ,pp. : 87-92

Elsevier

Access to resources Recommend Favorite

Switching from oral antipsychotics to long-acting risperidone

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review

Current Clinical Pharmacology, Vol. 8, Iss. 3, 2013-08 ,pp. : 256-264

Bentham Science Publishers

Access to resources Recommend Favorite

Long-Acting Injectable Antipsychotics for the Maintenance Treatment of Bipolar Disorder

By >

CNS Drugs, Vol. 26, Iss. 5, 2012-05 ,pp. : 403-420

Adis International

Access to resources Recommend Favorite

Long-Acting Injectable Antipsychotics in the Elderly: Guidelines for Effective Use

By Masand P.S.

Drugs & Aging, Vol. 20, Iss. 15, 2003-01 ,pp. : 1099-1110

Adis International

Access to resources Recommend Favorite